Substituted piperaziniums for the treatment of emesis
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK 1 ) receptor. The compounds have the general formula (I):
1. A compound of formula (VI):
or a pharmaceutically acceptable salt thereof,
wherein:
(a) R 2 , R 5 and R 6 are each independently hydrogen;
(b) m, p and s are each independently zero; and
(c) R 200 and R 300 are each independently selected from the group consisting of hydrogen and methyl.
2. A chloride hydrochloride salt of a compound of formula (VI):
wherein:
(a) R 2 , R 5 and R 6 are each independently hydrogen;
(b) m, p and s are each independently zero; and
(c) R 200 and R 300 are each independently selected from the group consisting of hydrogen and methyl.
3. A parenteral pharmaceutical composition comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and one or more liquid pharmaceutical excipients.
4. The parenteral composition of claim 3 , wherein the parenteral composition further comprises palonosetron, or a pharmaceutically acceptable salt thereof.
5. A parenteral pharmaceutical composition comprising a chloride hydrochloride salt of a compound of formula (I):
and one or more liquid pharmaceutical excipients.
6. The parenteral composition of claim 5 , wherein the parenteral composition further comprises palonosetron, or a pharmaceutically acceptable salt thereof.